what's new in myeloproliferative neoplasms?
Published 8 years ago • 350 plays • Length 1:45Download video MP4
Download video MP3
Similar videos
-
5:06
new insights in the biology of myeloproliferative neoplasms
-
2:06
an insight into the challenges and management of myeloproliferative neoplasm-unclassifiable (mpn-u)
-
1:33
the need for novel therapeutic agents in myeloproliferative neoplasms
-
1:12
contemporary challenges in polycythemia vera management
-
1:07
advancements in combination strategies with jak inhibitors for myelofibrosis
-
1:05:24
understanding myeloproliferative neoplasms diagnosis, treatments and follow up care
-
1:00:46
ask an mpn expert: tracking and living with mpns
-
24:35
first symptoms & treatment options in 2024 | myelofibrosis | the patient story
-
2:16
the current state-of-the-art in mf and pv therapy and future outlooks
-
4:00
update on clinical trials for myeloproliferative neoplasms
-
4:03
the earlier the better: detecting target genes in myeloproliferative neoplasms
-
3:05
the importance of non-pharmacological interventions in myeloproliferative neoplasms
-
6:13
blood review series – myeloproliferative neoplasms
-
1:48
promising clinical trials for myeloproliferative neoplasms
-
1:26
current and emerging prognostic factors for mds/mpn
-
4:48
an insight into the management of cytopenias in mf
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
6:00
covid-19 and mpn updates
-
4:12
covid-19 and mpn
-
2:03
myeloproliferative neoplasms: what’s happening inside the body
-
1:46
how would the approval of luspatercept benefit the treatment landscape in myelofibrosis
-
2:03
prognostic significance of molecular mrd in npm1-mutated aml treated with venetoclax-based therapy